Arvinas announced its third quarter 2026 financial results, highlighting progress in clinical trials for several PROTAC drug candidates targeting cancers and neurological diseases. Key updates include dosing initiation in a Phase 1/2 trial for ARV-6723, an immuno-oncology drug, and promising biomarker data for ARV-102 in Parkinson’s disease. The company expects to share important clinical data from ARV-393, ARV-027, and ARV-6723 in late 2026 and 2027, aiming to transform treatment options. Financially, Arvinas reported $558.9 million in cash and equivalents, sufficient to fund operations into late 2028.
Arvinas third quarter 2026 financial results provide context for readers. For those tracking health sector stocks, 74 of 150 US stocks rose and 69 fell on Pluang. Notable movers include RVTY at USD 165.01 (+8.81%), NBIX at USD 154.08 (+6.01%, 100% sell orders), and PHG at USD 29.23 (+5.94%). Data is as of Nov 03, 2026 19:02 WIB.
Anavex Life Sciences appointed Terrie Kellmeyer, Ph.D., as President and CEO, also joining the Board. Kellmeyer, with over 30 years in biopharma, has led the company through key clinical milestones including FDA clearance for Fragile X syndrome trial...
Cardiff Oncology, a clinical-stage biotech company focusing on cancer therapies via PLK1 inhibition, announced it will present at the UBS Global Biopharma Conference on November 16-17, 2026. The company's CEO, Mani Mohindru, will deliver a fireside c...
Seyond Inc is enhancing its smart city solutions by integrating advanced LiDAR 3D sensing with AI-powered analytics and collaborations with Dell Technologies, NVIDIA, and AMSYS. This expansion supports improved safety, transportation, and infrastruct...
Stella-Jones Inc. announced a teleconference on November 4, 2026, at 10:00 AM EST to discuss its third-quarter 2026 financial results. The event is open to investors, analysts, and interested parties, with live streaming and phone access provided. A ...
Stella-Jones Inc. announced a conference call for November 4, 2026, at 10:00 AM EST to discuss its third quarter 2026 financial results. The call is open to investors, analysts, and interested parties and will be webcast live with a recording availab...
